“Following our previous announcement that the tovecimig Phase 2/3 trial met the primary endpoint of overall response rate, we are encouraged to see fewer deaths in the study than we originally modeled. Because the analysis of the secondary endpoints of progression-free survival and overall survival is triggered by total deaths in the study, we are updating our guidance on the secondary endpoint analyses to Q1 2026,” said Thomas Schuetz, MD, PhD, Chief Executive Officer and Vice Chairman of the Board of Directors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics: Promising Clinical Trials and Strategic Confidence Drive Buy Rating
- Promising Outlook for Compass Therapeutics: Buy Rating Backed by Tovecimig’s Potential and Strategic Positioning
- Compass Therapeutics resumed with an Outperform at Raymond James
- Compass Therapeutics Completes Phase 2 Study on CTX-009 for Metastatic Colorectal Cancer
- Compass Therapeutics Confirms Directors at Annual Meeting